HLA-matched PT/CY

Phase I/II study of HSCT from HLA-matched donor using post-transplant cyclophosphamide - HLA-matched PT/CY

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180140

Enrollment

Registered

2019-02-20

Start date

2018-10-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AML, ALL, NHL, MDS

Interventions

50 mg/kg of cyclophosphamide on day 3, 4

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) AML, ALL, NHL, MDS 2) age 16-60 3) possessing allele 8/8 matched donor (age 16-60) 4) PS == 40% 6) SpO2 >= 90% 7) %VC >= 70% and FEV1.0% >= 70% 8) Bil == 30 ml/min

Exclusion criteria

Exclusion criteria: 1) positive for HBs Ag 2) positive for HIV Ab 3) depression 4) pregnancy 5) coexisting active cancer 6) active infection 7) pentostatin administration 8) hypersensitivity to cyclophosphamide

Design outcomes

Primary

Measure	Time frame
Success rate at 6 months.	—

Secondary

Measure	Time frame
engraftment acute GVHD (grade 2-) chronic GVHD non-relapse mortality	—

Contacts

Public ContactNaoki Kurita

University of Tsukuba Hospital

kuripon@mvb.biglobe.ne.jp+81-29-853-3127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026